𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point?

✍ Scribed by Pavlo Ohorodnyk; Elizabeth A. Eisenhauer; Christopher M. Booth

Book ID
116430093
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
101 KB
Volume
45
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Benefits of Aldosterone Receptor Antagon
Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25
✍ Hill, Nathan R; Lasserson, Daniel; Thompson, Ben; Perera-Salazar, Rafael; Wolste πŸ“‚ Article πŸ“… 2014 πŸ› BioMed Central 🌐 English βš– 315 KB